RT期刊文章SR电子T1腺相关病毒(AAV)——卵泡介导过分生长(FS)基因转移毒理学研究,准备第一阶段临床试验(SC02.004)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP SC02.004 OP SC02.004 VO 78是1补充A1 Janaiah哥打A1克里斯托弗先令A1水晶蒙哥马利A1莎拉·刘易斯A1亚首页当·贝文A1金正日Shontz A1较Kaminoh A1 Xiomara罗萨莱斯A1劳伦斯Viollet A1凯文Flanigan A1里德Brian卡斯帕·克拉克A1 A1 Zarife Sahenk A1杰瑞Mendell说年2012 UL //www.ez-admanager.com/content/78/1_Supplement/SC02.004.abstract AB目的:建立rAAV.CMV安全。FS基因转移的肌内注射(坜)为提高股四头肌的力量,准备第一阶段的临床试验。背景FS是一个强有力的肌肉生长抑制素抑制剂,增加肌肉的大小和强度在老鼠和非人类的灵长类动物肌肉交付由AAV分泌。安全问题包括阻碍pituitary-gonadal轴激素的释放和通用器官毒性。在本研究中我们使用non-tissue绑定FS同种型(FS344)来解决这些安全问题在小鼠病毒剂量10倍高于计划在临床使用。设计/方法:小鼠被随机分配到三实验武器与双边贝聿铭rAAV1.CMV的股四头肌肌肉注射。FS344等于最高的临床剂量(2.0 e12汽油vg /公斤)或高10倍(2.0 e13 vg /公斤)。动物是牺牲时间点在6 - 12个月、24和36周(5动物/性/组/计算)post-injection (p)。结果包括:体重、血液学、化学面板、pituitary-gonadal激素;免疫研究,组织病理学24从每个动物器官。结果:没有观察和治疗相关的不良临床或毒理学迹象表明病毒DNA在身体组织中消散了24周。在6周内,高剂量动物显示散焦浸润的炎症细胞与t细胞免疫AAV1有关酶联免疫斑点,被IFN-γ但没有其他病理观察。潮湿的股四头肌的重量增加了3.5倍在36周pi高剂量的动物。 Muscle fiber hypertrophy was observed at 6 weeks and fiber diameter increased by 50% compared to controls by 36 weeks. Hypertrophic-multinucleated fibers were observed at 12 weeks p.i. with increased density of PAX7 positive nuclei.Conclusions: This study shows rAAV1.CMV.FS344 is safe and well tolerated at the proposed clinical doses and causes satellite cell proliferation and significant muscle hypertrophy by fusion with differentiated satellite cells. Early transient inflammation in muscle is related to immune response to AAV1. These results support this approach for clinical trial use.Supported by: Grants from The Myositis Association and Parent Project Muscular Dystrophy, Inc; and support from the Foundation at Nationwide Children's Hospital.Disclosure: Dr. Kota has nothing to disclose. Dr. Shilling has nothing to disclose. Dr. Montgomery has nothing to disclose. Dr. Lewis has nothing to disclose. Dr. Bevan has nothing to disclose. Dr. Shontz has nothing to disclose. Dr. Kaminoh has nothing to disclose. Dr. Rosales has nothing to disclose. Dr. Viollet has nothing to disclose. Dr. Flanigan has received personal compensaiton for activities with AVI Therapeutics, Prosensa Therapeutics, and PTC, Inc. Dr. Flanigan has received research support from PTC Therapeutics. Dr. Clark has nothing to disclose. Dr. Kaspar has nothing to disclose. Dr. Sahenk has nothing to disclose. Dr. Mendell has received research support from AVI BioPharmaceuticals Inc.Friday, April 27 2012, 09:00 am-17:00 pm